IL1A and type 2 diabetes mellitus: Pharmacological inhibition of IL-1R signaling, for example, with clinically approved IL-1R antagonists such as anakinra,43,44 may represent a promising strategy, since anakinra has demonstrated clinical benefit in several IL-1 driven conditions, including type 2 diabetes and atherosclerosis.45